The Orthopaedic Implant Company (OIC) commenced U.S. launch of its Antegrade/Retrograde Intramedullary Femur Nail system (ARFN).
The ARFN Nail is designed to treat femoral midshaft and distal fractures, providing retrograde and antegrade approaches in one design, and uses the same instrumentation as all IM nails from OIC. ARFN represents the second IM nail launched by OIC within 2016.
OIC implants are reported to cost cost 50% to 60% less than the average market price of premium implants. All OIC products are FDA cleared.
The Orthopaedic Implant Company (OIC) commenced U.S. launch of its Antegrade/Retrograde Intramedullary Femur Nail system (ARFN).
The ARFN Nail is designed to treat femoral midshaft and distal fractures, providing retrograde and antegrade approaches in one design, and uses the same instrumentation as all IM nails from OIC. ARFN represents the...
The Orthopaedic Implant Company (OIC) commenced U.S. launch of its Antegrade/Retrograde Intramedullary Femur Nail system (ARFN).
The ARFN Nail is designed to treat femoral midshaft and distal fractures, providing retrograde and antegrade approaches in one design, and uses the same instrumentation as all IM nails from OIC. ARFN represents the second IM nail launched by OIC within 2016.
OIC implants are reported to cost cost 50% to 60% less than the average market price of premium implants. All OIC products are FDA cleared.
Copy to clipboard 
